DATA GRAPHICS | Product Development
Data Bytes: Regeneron leads COVID-19 antiviral antibody pack
August 12, 2020 3:10 AM UTC
The earliest efficacy signal among the eight SARS-CoV-2 neutralizing mAb therapies in the clinic could come from Regeneron, which expects to report early data for its REGN-COV2 antibody cocktail this summer.
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is running a trio of trials, one each in the outpatient, hospital and prevention settings. The biotech last week published data in bioRxiv showing that monkeys treated with REGN-COV2 three days before or one day after SARS-CoV-2 challenge had faster viral clearance than placebo (see “ Data From Regeneron mAb Cocktail”)...